Treatment of Relapsed B/T-cell Mixed Phenotype Acute Leukemia With Blinatumomab.

Abstract

Here, we describe the treatment of a patient with relapsed/refractory B/T mixed phenotype acute leukemia (MPAL) using blinatumomab monotherapy, the first bispecific T cell engager (BiTE) approved by the FDA for relapsed/refractory B cell acute lymphoblastic leukemia (B-ALL). A 64-year-old man with a history of stage 3 chronic kidney disease and type 2 diabetes mellitus was discovered to have B/T MPAL on bone marrow biopsy during hospitalization for dyspnea due to pulmonary embolism. The patient achieved brief remission with blinatumomab treatment before succumbing to neutropenic sepsis. The lack of sufficient data to guide therapy in MPAL remains a challenge, highlighting the potential of new targeted approaches such as blinatumomab to improve outcomes in relapsed/refractory MPAL.

• Authors: Yasmeen Abdo, Geoffrey D Gibson, Sarika P Jain, Carter P Milner, Talal Hilal
• Journal: Cureus (Cureus) Vol. 15 Issue 6 Pg. e40661 (Jun 2023) ISSN: 2168-8184 [Print] United States
• PMID: 37485162 (Publication Type: Case Reports)
• Copyright: Copyright © 2023, Abdo et al.